Markers of Inflammation after Simvastatin in Ischemic Cortical Stroke "MISTICS"

Completed

Phase N/A Results

Results

Patients receiveing Simvastatin improved significantly by day 3 (46.4% vs 17.9%, p<0.022) and had a greater improvement in NIHSS scores at day 90 (-9 points vs -5 points). The Simvastatin group had a higher proportion of patients with great improvement (decrease of more than 8 NIHSS points) at day 90 (10 vs 3, p<0.044) and a higher proportion of patients with dramatic improvement (decrease of 10 points) at day 90 (11 vs 4, p<0.035).